Agenzia Italiana del Farmaco
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 October 2025 - Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 October 2025
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 October 2025
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) – 27-30 October 2025:
Injectable tranexamic acid
- Safety issue: Cases of medication errors have been reviewed in which tranexamic acid was mistakenly administered intrathecally or epidurally, due to confusion with other medications, particularly local anesthetics. Patients experienced serious adverse reactions, including severe pain localized to the back, buttocks, and lower limbs, seizures, cardiac arrhythmias, and, in some cases, death.
- Communications/Recommendations: The PRAC recommends to disseminate Direct Healthcare Professionals Communication (DHPC) about the use of injectable tranexamic acid in order to prevent such errors, reminding that the medicine should only be administered intravenously. The PRAC also recommends to clearly label syringes with the words "for intravenous use only" and storing tranexamic acid separately from local anaesthetics.
Published on: 31 October 2025
#AIFA pubblica il Rapporto #OsMed 2025 sull’uso dei #farmaci in Italia.
Dati principali ⬇️
💊 Nel ...
Vai al post →
📢 Il CdA #AIFA approva la rimborsabilità di 4 nuovi #farmaci, 4 estensioni di indicazione terapeuti...
Vai al post →
🔎 "Cerca un farmaco": novità da AIFA
Il servizio #AIFA Medicinali, accessibile anche dalla home de...
Vai al post →
Via libera del CdA #AIFA alla rimborsabilità di una nuova molecola, 10 estensioni di indicazione ter...
Vai al post →
L'Italia si conferma tra i primi Paesi europei per l'accesso ai #farmaci orfani rimborsati dal Servi...
Vai al post →
💜 Il 29 giugno #AIFA si è illuminata di viola in occasione della XVII Giornata Mondiale della Scler...
Vai al post →
